Monopar Therapeutics (NASDAQ:MNPR) Coverage Initiated by Analysts at BTIG Research

BTIG Research began coverage on shares of Monopar Therapeutics (NASDAQ:MNPR) in a research note published on Tuesday, MarketBeat.com reports. The brokerage issued a buy rating and a $87.00 price target on the stock.

Several other brokerages have also issued reports on MNPR. Oppenheimer initiated coverage on shares of Monopar Therapeutics in a research note on Wednesday, September 3rd. They issued an “outperform” rating and a $77.00 price target on the stock. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $74.00 target price on shares of Monopar Therapeutics in a research report on Wednesday, August 27th. Chardan Capital reissued a “buy” rating and set a $60.00 price target on shares of Monopar Therapeutics in a research report on Wednesday, August 13th. HC Wainwright started coverage on Monopar Therapeutics in a research note on Tuesday, August 26th. They issued a “buy” rating and a $70.00 price target for the company. Finally, Raymond James Financial started coverage on Monopar Therapeutics in a research note on Tuesday, September 2nd. They set a “strong-buy” rating and a $80.00 price objective on the stock. One research analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating and one has given a Hold rating to the stock. According to MarketBeat, the stock currently has a consensus rating of “Buy” and a consensus target price of $71.75.

Monopar Therapeutics Stock Performance

Shares of Monopar Therapeutics stock opened at $47.67 on Tuesday. The firm has a market cap of $294.12 million, a PE ratio of -14.32 and a beta of 1.20. The business’s 50 day simple moving average is $39.06 and its 200 day simple moving average is $36.76. Monopar Therapeutics has a 52-week low of $3.17 and a 52-week high of $54.30.

Monopar Therapeutics (NASDAQ:MNPR) last issued its quarterly earnings results on Tuesday, August 12th. The company reported ($0.35) earnings per share for the quarter, topping the consensus estimate of ($0.47) by $0.12. As a group, equities research analysts predict that Monopar Therapeutics will post -1.65 EPS for the current year.

Insider Buying and Selling at Monopar Therapeutics

In other news, Director Christopher M. Starr sold 16,800 shares of Monopar Therapeutics stock in a transaction that occurred on Monday, July 14th. The stock was sold at an average price of $40.00, for a total transaction of $672,000.00. Following the completion of the transaction, the director directly owned 5,173 shares in the company, valued at approximately $206,920. The trade was a 76.46% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, Director Kim R. Tsuchimoto sold 8,904 shares of the stock in a transaction on Monday, July 14th. The shares were sold at an average price of $40.00, for a total value of $356,160.00. Following the completion of the sale, the director owned 11,486 shares in the company, valued at approximately $459,440. This trade represents a 43.67% decrease in their position. The disclosure for this sale can be found here. Insiders have sold 42,504 shares of company stock worth $1,700,160 over the last 90 days. Company insiders own 20.50% of the company’s stock.

Institutional Trading of Monopar Therapeutics

Hedge funds and other institutional investors have recently modified their holdings of the stock. Janus Henderson Group PLC acquired a new position in Monopar Therapeutics in the 4th quarter valued at about $23,435,000. Point72 Asset Management L.P. acquired a new position in shares of Monopar Therapeutics in the fourth quarter valued at approximately $3,694,000. Gerber LLC acquired a new position in shares of Monopar Therapeutics in the first quarter valued at approximately $204,000. AlphaQuest LLC bought a new position in shares of Monopar Therapeutics during the first quarter worth approximately $44,000. Finally, Affinity Asset Advisors LLC acquired a new stake in Monopar Therapeutics during the 1st quarter worth approximately $2,257,000. Institutional investors own 1.83% of the company’s stock.

Monopar Therapeutics Company Profile

Monopar Therapeutics Inc, a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. Its lead product candidate in development is Validive, a clonidine hydrochloride mucobuccal tablet that is in Phase 2b/3 clinical trial for the prevention of chemoradiotherapy induced severe oral mucositis in patients with oropharyngeal cancer.